Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a collaboration with Professor Melissa Little and the Murdoch Children's Research Institute, to develop an architecturally correct kidney for potential therapeutic applications. The collaboration has been made possible by a generous gift from the Methuselah Foundation (“Methuselah”) as part of its ongoing University 3D Bioprinter Program.
“Partnerships with world-class institutions can accelerate ground breaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues," said Keith Murphy, CEO, Organovo. “This collaboration with Professor Little’s lab is another important step in this direction. With the devoted and ongoing support of the Methuselah Foundation, leading researchers are able to leverage Organovo’s powerful technology platform to achieve significant breakthroughs.”
“We have developed an approach for recreating human kidney tissue from stem cells,” said Professor Melissa Little, Theme Director of Cell Biology at Murdoch Children's Research Institute. “Using Organovo’s bioprinter will give us the opportunity to bioprint these cells into a more accurate model of the kidney. While initially important for modelling disease and screening drugs, we hope that this is also the first step towards regenerative medicine for kidney disease. We are very grateful to Organovo and the Methuselah Foundation for this generous support, which will enable us to advance our research with the first Organovo bioprinter in the southern hemisphere.”
Under Methuselah Foundation's University 3D Bioprinter Program, Methuselah is donating at least $500,000 in direct funding to be divided among several institutions for Organovo bioprinter research projects. This funding will cover budgeted bioprinter costs and key aspects of project execution.
"We at the Methuselah Foundation have been a long-time supporter of academic and industry research in 3D bioprinting, regenerative medicine, and tissue engineering," said David Gobel, CEO, Methuselah Foundation. "Our University 3D Bioprinter Program puts Organovo’s breakthrough 3D bioprinting technology in the hands of the brightest scientists at tissue engineering centers of excellence."
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
About Murdoch Children's Research Institute
Murdoch Children's undertakes research into infant, child and adolescent health. As the largest child health research institute in Australia, our 1900 researchers are working hard to translate the knowledge we create from our research into effective prevention, early intervention and treatments for children. We strive for a healthier community, fewer sick kids visiting hospitals, and the best possible care for children who unfortunately become ill. The Murdoch Children's has a proud history of scientific discovery since its inception in 1986, and is currently based at The Royal Children’s Hospital in Melbourne, Australia. For more information please visit: www.mcri.edu.au.
About Methuselah Foundation
The Methuselah Foundation is a non-profit medical charity working to create a world where 90 year olds can have the health profile of 50 year olds, by 2030. By opportunistically leveraging resources, enabling partnerships, and awarding prizes and grants, we accelerate disruptive developments in biomedical engineering that will eradicate needless suffering and extend healthy human life. For more information please visit: www.methuselahfoundation.org and www.neworgan.org.
Available for interview:
Professor Melissa Little
Inga Feitsma, Communications Manager MCRI – 03 9936 6336 OR 0408 657 741
Katherine Loftus, Senior Communications Adviser MCRI – 03 8341 6269 OR 0416 013 689